C4 Therapeutics Inc
NASDAQ:CCCC
Income Statement
Earnings Waterfall
C4 Therapeutics Inc
Revenue
|
20.8m
USD
|
Operating Expenses
|
-159.8m
USD
|
Operating Income
|
-139m
USD
|
Other Expenses
|
6.5m
USD
|
Net Income
|
-132.5m
USD
|
Income Statement
C4 Therapeutics Inc
Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||
Revenue |
34
N/A
|
34
+0%
|
46
+35%
|
46
+0%
|
50
+9%
|
48
-3%
|
31
-36%
|
27
-13%
|
16
-41%
|
20
+27%
|
21
+2%
|
|
Operating Income | ||||||||||||
Operating Expenses |
(114)
|
(120)
|
(128)
|
(139)
|
(148)
|
(155)
|
(161)
|
(162)
|
(161)
|
(160)
|
(160)
|
|
Selling, General & Administrative |
(26)
|
(31)
|
(33)
|
(39)
|
(40)
|
(41)
|
(43)
|
(41)
|
(41)
|
(42)
|
(42)
|
|
Research & Development |
(88)
|
(89)
|
(95)
|
(100)
|
(108)
|
(114)
|
(118)
|
(121)
|
(119)
|
(118)
|
(118)
|
|
Operating Income |
(80)
N/A
|
(86)
-7%
|
(82)
+4%
|
(93)
-13%
|
(98)
-6%
|
(107)
-8%
|
(130)
-22%
|
(134)
-4%
|
(145)
-8%
|
(140)
+3%
|
(139)
+1%
|
|
Pre-Tax Income | ||||||||||||
Interest Income Expense |
(7)
|
(4)
|
(2)
|
(2)
|
(1)
|
(0)
|
1
|
3
|
5
|
7
|
8
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
|
Pre-Tax Income |
(87)
N/A
|
(90)
-3%
|
(84)
+7%
|
(95)
-13%
|
(99)
-5%
|
(107)
-7%
|
(128)
-20%
|
(131)
-2%
|
(140)
-6%
|
(134)
+4%
|
(131)
+2%
|
|
Net Income | ||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
|
Income from Continuing Operations |
(87)
|
(90)
|
(84)
|
(95)
|
(99)
|
(107)
|
(128)
|
(131)
|
(140)
|
(135)
|
(132)
|
|
Net Income (Common) |
(82)
N/A
|
(80)
+3%
|
(84)
-5%
|
(95)
-13%
|
(99)
-5%
|
(107)
-7%
|
(128)
-20%
|
(131)
-2%
|
(140)
-6%
|
(135)
+4%
|
(132)
+2%
|
|
EPS (Diluted) |
-1.87
N/A
|
-1.64
+12%
|
-1.82
-11%
|
-1.94
-7%
|
-2.04
-5%
|
-2.18
-7%
|
-2.62
-20%
|
-2.68
-2%
|
-2.85
-6%
|
-2.75
+4%
|
-2.67
+3%
|